[Cyclophosphamide-induced bladder cancer in a patient with Wegener granuromatosis]

Nihon Hinyokika Gakkai Zasshi. 1999 Jan;90(1):53-6. doi: 10.5980/jpnjurol1989.90.53.
[Article in Japanese]

Abstract

Cyclophosphamide (CPM) has been considered to be a factor of bladder carcinogen. A 60-years old woman had been received a total dose of 370 g of CPM for the treatment of Wegener's granulomatosis since August, 1977. She was consulted to our department with chief complaint of macrohematuria in August, 1986. Hemorrhage cystitis was diagnosed and cystoscopy and urine cytology were performed as follow-up schedule in every year. In 1996, urine cytology showed class IV and cystoscopy revealed multiple nonpapillary tumors. Abdominal computerized tomography demonstrated a low density mass on the posterior wall of the bladder. A transurethral cold cup biopsy showed G3 transitional cell carcinoma (TCC). Radical cystectomy and tubeless cutaneous ureterostomy was performed on December 6, 1996 and histopathological diagnosis was TCC, G 3, pT3 bNXM0. She died of liver failure due to metastatic bladder cancer after seven months postoperatively.

Publication types

  • Case Reports
  • English Abstract
  • Review

MeSH terms

  • Carcinoma, Transitional Cell / chemically induced*
  • Carcinoma, Transitional Cell / secondary
  • Cyclophosphamide / adverse effects*
  • Fatal Outcome
  • Female
  • Granulomatosis with Polyangiitis / drug therapy*
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Liver Failure / etiology
  • Liver Neoplasms / secondary
  • Middle Aged
  • Urinary Bladder Neoplasms / chemically induced*
  • Urinary Bladder Neoplasms / pathology

Substances

  • Immunosuppressive Agents
  • Cyclophosphamide